Clinical Trial Update: Gefitinib in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer or Primary Peritoneal Cancer [Phase 2]

View source ↗

Summary

The document reports results from a completed Phase 2 trial of gefitinib in patients with recurrent or persistent ovarian epithelial cancer or primary peritonea…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Gefitinib (Iressa) (gefitinib)

Snippet

Sponsor: Gynecologic Oncology Group | Conditions: Ovarian Cancer, Primary Peritoneal Cavity Cancer | Phase 2 | Status: COMPLETED